Qube Research & Technologies (QRT)
PRLD icon

Qube Research & Technologies (QRT)’s Prelude Therapeutics PRLD Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$56.1K Sell
16,417
-5,134
-24% -$13.5K ﹤0.01% 3153
2025
Q4 		$62.5K Buy
+21,551
New +$36.4K ﹤0.01% 3258
2024
Q3 		– Sell
-3,126
Closed -$11.9K – 3935
2024
Q2 		$11.9K Buy
+3,126
New +$12.7K ﹤0.01% 2947
2023
Q2 		– Sell
-30,377
Closed -$173K – 2871
2023
Q1 		$173K Buy
30,377
+17,250
+131% +$105K ﹤0.01% 1984
2022
Q4 		$79.3K Buy
+13,127
New +$84.1K ﹤0.01% 2053
2022
Q1 		– Sell
-23,384
Closed -$291K – 2875
2021
Q4 		$291K Buy
+23,384
New +$380K ﹤0.01% 1819

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Qube Research & Technologies (QRT)'s PRLD Position: Q1 2026 in Review

Qube Research & Technologies (QRT) reduced its Prelude Therapeutics (PRLD) stake by 24% in Q1 2026, selling an estimated $13.5K and leaving 16,417 shares worth $56.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3153.

Qube Research & Technologies (QRT) first reported a position in PRLD in Q4 2021 and has held it in 6 quarters since. The position peaked at $291K in Q4 2021. 55 funds tracked by Wall St. Rank hold PRLD as of Q1 2026.

  • Qube Research & Technologies (QRT) held 16,417 shares of Prelude Therapeutics worth $56.1K as of Q1 2026.
  • Qube Research & Technologies (QRT) sold 5,134 Prelude Therapeutics shares in Q1 2026, an estimated $13.5K.
  • Prelude Therapeutics made up ﹤0.01% of Qube Research & Technologies (QRT)'s portfolio in Q1 2026, its #3153 holding.
  • Qube Research & Technologies (QRT) first reported a position in Prelude Therapeutics in Q4 2021 and has held it in 6 quarters since.
  • Qube Research & Technologies (QRT)'s Prelude Therapeutics position peaked at $291K in Q4 2021.
  • 55 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.